Celgene Implements Commercial Co-pay program for ISTODAX®

Celgene has recently implemented a Celgene Commercial Co-pay Program for eligible patients taking ISTODAX® (romidepsin) for injection. To qualify for the program, a patient must: (i) have an annual household income of less than $100,000, (ii) maintain commercial or private health insurance, and (iii) reside in the United States or Puerto Rico. Certain qualifying patients may be eligible to reduce their out-of-pocket co-pay responsibility for ISTODAX to $0. Also, co-pay assistance may be available for patients who have Medicare, Medicaid, or other government- sponsored insurance through unaffiliated, independent, third-party organizations such as the Patient Access Network Foundation.


Your patients can find out more about these programs and others by calling Celgene Patient Support® at 1-800-931-8691, Monday – Friday, 8 AM – 7 PM ET.

Updated Labeling for Celgene's POMALYST®

Celgene recently announced an updated labeling for POMALYST® for use in  multiple myeloma. Please Click Here for an announcement of these important updates.

Top 5 Claims Mistakes Video

Click Here to view a Short Video on How to Avoid Common Documentation Errors

News Update for Oncotype DX®

On May 11, 2015 Genomic Health announced the following:

St. Gallen International Breast Cancer Guidelines Selects Oncotype DX® as the Only Multi-Gene Test Validated to Predict Chemotherapy Benefit

Congress Passes Bill to Repeal SGR

Late last night, the Senate passed H.R. 2, the “Medicare Access and Chip Reauthorization Act,” (MACRA), by a vote of 92-8. This bill is the same bill that was passed by the House on March 26 by a vote of 392-37.The bill now goes to President Obama for his signature. 

Among the bill’s significant provisions:

  • Replaces the SGR with an increase of 0.5% in Medicare physician reimbursement starting in July 2015 through December 2015, and then annual 0.5% increases lasting through 2019.
  • Consolidates reporting programs, such as the Meaningful Use program for electronic health records and several quality reporting programs, into a new, merit-based incentive payment system.
  • Incentivizes physicians to participate in alternative payment models such as accountable care organizations (ACOs).
  • Extends the floor on the Work GPCI.
  • Implements income-related premium adjustments for Parts B and D for higher-income Medicare beneficiaries. 

We will post additional information on this historic bill once we have had time to thoroughly review it. 

CLICK HERE to Read the bill as passed by Congress.

BMS Receives New Approval for Opdivo

On March 4, 2015, Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Opdivo is the first and only PD-1 (programmed death receptor-1) therapy to demonstrate overall survival in previously treated metastatic squamous NSCLC.

Click Here to read the News Release and full Prescribing Information.

Click Here to access the Opdivo Fact Sheet

New Liquid Formulation of KEYTRUDA®

Merck Sharp & Dohme Corp. (Merck), a subsidiary of Merck & Co., Inc., is pleased to announce the availability of a liquid formulation of KEYTRUDA. Merck expects to make this product available on or after February 16, 2015. Check with your authorized distributor for details. This 100-mg liquid vial will replace the 50-mg lyophilized formulation, which was launched as a transition image until the liquid formulation was available. The price per mg has not changed with the introduction of this image.

Click Here to read the notice with important NDC and coding information.

Click Here for the Prescribing Information.

Click Here for the Medication Guide.


Neulasta® Delivery Kit Now Available

A new administration option for Neulasta® is now available: the Neulasta® Delivery Kit.  

The Neulasta® Delivery Kit (NDC: 55513-192-01) requires administration by a healthcare provider and is available at the same WAC (wholesale acquisition cost) as the currently available Neulasta® prefilled syringe (NDC:  55513-190-01).

Neulasta® is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Neulasta® is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. 

Please click here for the Neulasta® Prescribing Information. 

Please click here for the On-body Injector for Neulasta® Instructions for Use.